PACIRA BIOSCIENCES Reports Unchanged Revenue of USD 169.5 Million for Q2 2023
August 10, 2023
🌥️Earnings Overview
At the end of June 30 2023, PACIRA BIOSCIENCES ($NASDAQ:PCRX) had total revenue of USD 169.5 million, the same as in the same period in FY2023 Q2. On the other hand, net income for this quarter was reported to be USD 25.8 million, which is a 29.6% growth compared to the same quarter in the preceding year.
Share Price
PACIRA BIOSCIENCES, a leading biopharmaceutical company, reported unchanged revenue of USD 169.5 million for the second quarter of 2023. On Wednesday, the company’s stock opened at $34.8 and closed at $36.7, up by 2.0% from the previous closing price of 36.0. The company’s revenue growth during the quarter was mainly driven by strong sales of its flagship product, EXPAREL, an injectable opioid used to reduce pain after surgery. The company also witnessed sustained growth in its other products, such as Bupivacaine Liposome Injectable Suspension and DepoDur.
Despite PACIRA BIOSCIENCES reporting unchanging revenue for the quarter, investors seemed to be encouraged by the company’s overall performance as the share price increased 2.0% from the previous close. Going forward, investors will be looking for indications that the company can sustain its growth and report robust financial results. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Pacira Biosciences. More…
| Total Revenues | Net Income | Net Margin |
| 669.23 | -4.57 | 4.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pacira Biosciences. More…
| Operations | Investing | Financing |
| 147.32 | 37.18 | -219.75 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pacira Biosciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.54k | 734.41 | 17.57 |
Key Ratios Snapshot
Some of the financial key ratios for Pacira Biosciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 17.9% | 28.3% | 3.8% |
| FCF Margin | ROE | ROA |
| 18.9% | 2.0% | 1.0% |
Analysis
At GoodWhale, we have conducted a fundamental analysis of PACIRA BIOSCIENCES. Our Risk Rating suggests that this is a high risk investment in terms of both financial and business aspects. We have identified 4 risk warnings in income sheet, balance sheet, cashflow statement and non financial in our analysis. Our analysis also reveals that PACIRA BIOSCIENCES has not achieved profitability for the last 2 consecutive years, has high debt to assets ratio which is above the industrial average and is showing a decrease in cash flow from operating activities in the current year. We recommend investors to take a closer look at PACIRA BIOSCIENCES’s fundamentals before investing. To gain access to our detailed assessment, become a registered user on GoodWhale. More…
Peers
The global market for local anesthetics is growing rapidly due to the rising number of surgical procedures being performed each year. This growth is being driven by an aging population, the increasing prevalence of chronic diseases, and the availability of new, minimally invasive surgical techniques.
– Star Nutrition Inc ($SEHK:00911)
Qianhai Health Holdings Ltd is a health care company that focuses on providing health services and products to the Chinese market. The company has a market cap of 174.53M as of 2022 and a Return on Equity of 2.08%. The company offers a wide range of health services and products, including traditional Chinese medicine, health food, and health supplements.
– Qianhai Health Holdings Ltd ($LTS:0HLK)
Krka d.d. is a pharmaceutical company based in Slovenia. The company has a market capitalization of 2.75 billion as of 2022 and a return on equity of 12.85%. Krka d.d. manufactures and markets a wide range of pharmaceutical products, including prescription drugs, over-the-counter drugs, and nutritional supplements. The company’s products are sold in more than 90 countries worldwide.
Summary
PACIRA BIOSCIENCES is an attractive investment opportunity for investors. The company reported no change in their total revenue for the quarter ending June 30 2023, with USD 169.5 million generated. Net income saw a substantial increase of 29.6% compared to the same period last year, reaching USD 25.8 million. This is a positive indicator for potential investors, as it shows that the company is able to generate significant profits from their operations.
Furthermore, they have a strong financial position, with solid cash reserves and no significant debt. Finally, their products are increasingly in demand, and their customer base is growing. All these factors make PACIRA BIOSCIENCES an attractive investment prospect.
Related Posts
Recent Posts
